Tenecteplase in Central Retinal Artery Occlusion Study (TenCRAOS): Protocol for a randomized-controlled trial
European Stroke Journal · 01.12.2025 · 10 (4) · 1502-1510
DOI: 10.1177/23969873251344199 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift European Stroke Journal, online erschienen am 01.12.2025. Verfasst von Stephen J Ryan und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Oslo University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Retinal Artery Occlusion, Tenecteplase, Fibrinolytic Agents, Tissue Plasminogen Activator. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Independent Order of Odd Fellows, Klinbeforsk, Helse Sør–Øst RHF.
Abstract (Originalsprache)
Rationale
Central retinal artery occlusion (CRAO) is an ophthalmologic emergency that, without prompt reperfusion, is associated with a high risk of permanent blindness. There is currently no evidence-based, effective treatment for CRAO. Methods and design: TenCRAOS is an investigator-initiated, international, multicenter, randomized controlled, double-dummy, double-blind, phase III trial testing tenecteplase (TNK) 0.25 mg/kg + placebo versus acetylsalicylic acid (ASA) 300 mg + placebo. The target population is patients diagnosed with CRAO and a best-corrected visual acuity (BCVA) of ⩾1.0 logarithm of the minimum angle of resolution (logMAR), corresponding to a decimal BCVA of ⩽0.1 or a fraction BCVA of ⩽6/60, who can be treated within 4.5 h. Sample size: Assuming a difference in proportion of participants reaching the primary endpoint of 20% in the placebo/ASA treatment group versus 50% in the TNK/placebo group, we need 78 participants to reach 80% power to detect the difference on a 5% significance level. Outcomes: The primary outcome is the proportion of participants with BCVA of ⩽0.7 logMAR in the affected eye at 30-day follow-up, corresponding to a decimal BCVA of ⩾0.2 or fraction BCVA of ⩾6/30, representing a clinically relevant improvement of BCVA of ⩾0.3 logMAR (or 15 letters). Secondary efficacy outcomes include proportion of participants with BCVA of ⩽0.5 logMAR, corresponding to a decimal BCVA of ⩾0.32 or fraction BCVA of ⩾ 6/19, self-reported vision-targeted health status, quality of life, and modified Rankin Score at 30 and 90 days. Safety outcomes include symptomatic intracranial hemorrhage, major bleeding, and mortality. Exploratory analyses include assessment with optical coherence tomography with angiography and transorbital ultrasound.
Discussion
TenCRAOS intends to assess the efficacy and safety of systemic TNK within 4.5 h of CRAO onset.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Oslo University Hospital, Oslo, Norway.
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
- Department of Ophthalmology, Oslo University Hospital, Oslo, Norway.
- Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Neurology, Helsinki University Hospital, Helsinki, Finland.
ORCID-Profile: Stephen J Ryan, Øystein Kalsnes Jørstad, Rolf Ankerlund Blauenfeldt, Petra Ijäs, Jørgen Krohn, Jelle Demeestere, Louisa M Christensen, Vaidas Matijosaitis, Dordi Austeng, Michael V Mazya, Åse Hagen Morsund, Peter Kelly, Christina Kefaloykos, Thor Håkon Skattør
Förderung
- Independent Order of Odd Fellows
- Klinbeforsk
- Helse Sør–Øst RHF
- Boehringer Ingelheim
Zitieren
APA
Ryan, S. J., Jørstad, Ø. K., Skjelland, M., Simonsen, C. Z., Bek, T., Blauenfeldt, R. A., Ijäs, P., Laitinen, A., Khanevski, A. N., Krohn, J., Rødahl, E., Lemmens, R., Demeestere, J., Cassiman, C., Nakstad, I., Evensen, K., Sandell, T., Hamann, S., Christensen, L. M., …, & Kraglund, K. L. (2025). Tenecteplase in Central Retinal Artery Occlusion Study (TenCRAOS): Protocol for a randomized-controlled trial. European Stroke Journal, 10(4), 1502-1510. https://doi.org/10.1177/23969873251344199
Vancouver
Ryan SJ, Jørstad ØK, Skjelland M, Simonsen CZ, Bek T, Blauenfeldt RA, et al. Tenecteplase in Central Retinal Artery Occlusion Study (TenCRAOS): Protocol for a randomized-controlled trial. European Stroke Journal. 2025;10(4):1502-1510. doi:10.1177/23969873251344199
BibTeX
@article{Ryan2025,
author = {Ryan, Stephen J and Jørstad, Øystein Kalsnes and Skjelland, Mona and Simonsen, Claus Z and Bek, Toke and Blauenfeldt, Rolf Ankerlund and Ijäs, Petra and Laitinen, Arja and Khanevski, Andrej N and Krohn, Jørgen and Rødahl, Eyvind and Lemmens, Robin and Demeestere, Jelle and Cassiman, Catherine and Nakstad, Ingvild and Evensen, Kristin and Sandell, Tiril and Hamann, Steffen and Christensen, Louisa M and Rosenbaum, Sverre and Matijosaitis, Vaidas and Zemaitiene, Reda and Ellekjær, Hanne and Austeng, Dordi and Truelsen, Thomas C and Mazya, Michael V and Träisk, Frank and Ylikotila, Pauli and Salmi, Ulpu and Jenssen, Kristian N and Lisether, Håvard and Breivik, Cathrine and Devik, Kristina and Honningsvåg, Lasse-Marius Sandes and Valaikienė, Jurgita and Cimbalas, Andrius and Malmberg, Vetle Nilsen and Anderson, Espen and De Raedt, Sylvie and Tusscher, Marcel Ten and Ligot, Noémie and Lipski, Deborah and Björck, Fredrik and Hamrin, Annelie and Solbakken, Tore and Tharaldsen, Ane Roushan and Farmen, Anette Huuse and Helgesen, Andreas and Johnsen, Stein Harald and Bertelsen, Geir and Morsund, Åse Hagen and Holen, Erik and Tveiten, Arnstein and Johannessen, Henrik B and Kelly, Peter and O'Neill, Evelyn and Roy, Ansar and Kefaloykos, Christina and Skattør, Thor Håkon and Kraglund, Kristian L},
title = {Tenecteplase in Central Retinal Artery Occlusion Study (TenCRAOS): Protocol for a randomized-controlled trial},
journal = {European Stroke Journal},
year = {2025},
volume = {10},
number = {4},
pages = {1502--1510},
doi = {10.1177/23969873251344199}
}
EUVIMED